BioStock: Stayble Therapeutics has initiated the phase IIb study in Spain

Stayble Therapeutics has now initiated the first clinic in Spain for its clinical phase IIb study with the drug candidate STA363 for chronic disc-related low back pain. Thus, the study is underway in all prospective study countries – the Netherlands, Russia and Spain. BioStock has contacted Andreas Gerward, CEO of Stayble Therapeutics, to hear his thoughts on the announcement.

Read the full article at

This is a press release from BioStock – Connecting Innovation & Capital.